Her-2/neu expression in breast cancer - A comparison of different diagnostic methods

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 1895-1900

  Benöhr, Peter ^a   Henkel, V ^a   Speer, R ^a   Vogel, U ^b   Sotlar, K ^b   Aydeniz, B ^a   Reiser, A ^c   Neubauer, H ^a   Tabiti, K ^c   Wallwiener, D ^a   Clare, S E ^d   Kurek, R ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Her 2 neu; Real time PCR

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DNA DETERMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MICRODISSECTION; ONCOGENE NEU; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2;

EID: 21344436604     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Harari D and Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19: 6102-6114, 2000.
2. Doherty JK, Bond C, Jardim A, Adelman JP and Clinton GM: The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 96: 10869-10874, 1999.
3. Reese DM and Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8, 1997.
4. Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Stem Cells 16: 413-428, 1998.
5. Yamauchi H, Stearns V and Hayes D: When is a tumour marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001.
6. Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17: 1983-1987, 1999.
7. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R and Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000.
8. Harris L, Liotheva V, Broadwater G and Ramirez M: Comparison of methods of measuring Her-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19: 1698-1706, 2001.
9. Eppenberger-Castori S, Kueng W, Benz C, Caduff R and Eppenberger U: Prognostic and predictive significance of ErbB-2 breast tumour levels measured by enzyme immunoassay. J Clin Oncol 19: 645-656, 2001.
10. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
11. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992.
12. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L and Liu ET: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998.
13. Moliterni A, Menard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S and Bonadonna G: HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 21: 458-462, 2003.
14. Norton L, Slamon DJ, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M and Shak S: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18: 127, 1999.
15. Tupps RR, Pettay JD, Roche PC, Soler MH, Jenkins RB and Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714-2721, 2001.
16. O'Malley F, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, Arneson N, Blackstein M and Andrulis I: Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Path 115: 504-511, 2001.
17. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M and Löhrs U: HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354-363, 2001.
18. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL and Wolmark N: Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 94: 852-854, 2002.
19. Schnitt SJ and Jacobs TW: Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 116: 806-810, 2001.
20. Beyser K, Gross C, Möller C, Tahiti K and Rüschoff J: Real-time quantification of HER2/neu gene amplification by LightCycler Polymerase Chain Reaction (PCR) - a new research tool. Biochemica 2: 15-18, 2001.
21. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W and McCready D: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340-1349, 1998.
22. Press MF, Hung G, Godophin W et al: Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777, 1994.
23. O'Malley F, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, Hundal H, Chambers AF, Turnbull DI and Bramwell V: The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Human Path 27: 955-963, 1996.
24. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY and Bernstein L: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20: 3095-3105, 2002.
25. DiGiovanna MP, Carter D, Flynn SD and Stern DF: Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu- overexpressing invasive human breast tumours. Br J Cancer 74: 802-806, 1996.
26. LightCycler-HER2/neu DNA Quantification Kit. Biochemica 2: 14-15, 2001.
27. Merkelbach-Bruse S, Wardelmann E, Behrens P, Losen I, Buettner R and Friedrichs N: Current diagnostic methods of Her-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol 27: 1565-1570, 2003.
28. Lehmann U, Glöckner S, Kleeberger W, Feist H, v Wasielewski R and Kreipe H: Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 156: 1855-1864, 2000.